key: cord-0863887-8ciwv99j
authors: SHERER, Morgan L.; LEI, Jun; CREISHER, Patrick; JANG, Minyoung; REDDY, Ramya; VOEGTLINE, Kristin; OLSON, Sarah; LITTLEFIELD, Kirsten; PARK, Han-Sol; URSIN, Rebecca L.; GANESAN, Abhinaya; BOYER, Theresa; Elsayed, Nada; BROWN, Diane M.; WALCH, Samantha N.; ANTAR, Annukka A.R.; MANABE, Yukari C.; JONES-BEATTY, Kimberly; CHRISTOPHER GOLDEN, William; SATIN, Andrew J.; SHEFFIELD, Jeanne S.; PEKOSZ, Andrew; KLEIN, Sabra L.; BURD, Irina
title: Pregnancy alters IL-1β expression and anti-viral antibody responses during SARS-CoV-2 infection
date: 2021-03-30
journal: Am J Obstet Gynecol
DOI: 10.1016/j.ajog.2021.03.028
sha: ca08bf10e128e1bd7701f7e467c03afc53531aa8
doc_id: 863887
cord_uid: 8ciwv99j

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the disease-causing pathogen of the COVID-19 pandemic, has resulted in morbidity and mortality worldwide. Pregnant women are more susceptible to severe COVID-19 disease and are at higher risk for preterm birth compared to uninfected pregnant women. Despite this evidence, the immunological effects of SARS-CoV-2 infection during pregnancy remain understudied. Objective To assess the impact of SARS-CoV-2 infection during pregnancy on inflammatory and humoral responses in maternal and fetal samples and compare antibody responses to SARS-CoV-2 among pregnant and non-pregnant women. Study Design Immune responses to SARS-CoV-2 were analyzed using samples from pregnant (n=33) and non-pregnant (n=17) women who had either tested positive (pregnant n=22; non-pregnant n=17) or negative for SARS-CoV-2 (pregnant n=11) at Johns Hopkins Hospital. We measured proinflammatory and placental cytokine mRNAs, neonatal Fc receptor (FcRn) expression, and tetanus antibody transfer in maternal and cord blood samples. Additionally, we evaluated anti-spike (S) IgG, anti-S-receptor binding domain (RBD) IgG, and neutralizing antibody (nAb) responses to SARS-CoV-2 in serum or plasma collected from non-pregnant women, pregnant women, and cord blood. Results SARS-COV-2 positive pregnant women expressed more IL1β, but not IL6, in blood samples collected within 14 days versus > 14 days after a confirmed SARS-CoV-2 test. Pregnant women with confirmed SARS-CoV-2 infection also had reduced anti-S-RBD IgG titers and were less likely to have detectable nAb as compared with non-pregnant women. Although SARS-CoV-2 infection did not disrupt FcRn expression in the placenta, maternal transfer of SARS-CoV-2 nAb was inhibited by infection during pregnancy. Conclusions SARS-CoV-2 infection during pregnancy was characterized by placental inflammation and reduced antiviral antibody responses, which may impact the efficacy of COVID-19 therapeutics in pregnancy. The long-term implications of placental inflammation for neonatal health also requires greater consideration.

were pregnant, and thes e women were more likely to require mechanical ventilation compared 112 to nonpregnant women 3 . P regnant women als o are at increas ed ris k of mortality following 113 S AR S -C oV -2 infection 4 , prompting the C D C to revis e their guidelines and include pregnant 114 women as an at ris k population for s evere C O V ID -19 dis eas e. S AR S -C oV-2 s urveillance of 115 pregnant women in Was hington s tate further reveals greater morbidity and mortality in pregnant 116 women with S AR S -C oV -2 infection, and s ugges ts pos sible underreporting in nationwide 117 s urveillance data 5 . In addition to maternal morbidity and mortality, the C D C reports that women 118 infected with S AR S -C oV -2 during pregnancy are at higher ris k for preterm birth 6 . B ecaus e 119 maternal immune activation can be as s ociated with advers e fetal outcomes , including preterm 120 birth 7,8 , it is pos s ible that S AR S -C oV -2 during pregnancy may have detrimental effects on the 121 developing fetus . 122 D uring pregnancy, a typical inflammatory res ponse to pathogens includes the s ecretion 123 of proinflammatory cytokines , s uch as IL -1β and IL -6, not only at the s ite of infection but in the 124 placenta as well; thes e cytokines can readily enter the amniotic cavity and interfere with normal 125 fetal development 7-9 . T hus , even in the abs ence of s evere maternal s ymptoms or fetal viral 126 infection, the maternal immune respons e to S AR S -C oV -2 could lead to s hort and long-term 127 J o u r n a l P r e -p r o o f consequences in the fetus and neonate 2,10-12 . At the same time, the maternal immune response 128

can also have a protective effect on neonatal health, including the placental Fc receptor (FcRn)-129 mediated transfer of SARS-CoV-2-specific antibodies transplacentally 13,14 . 130 In the present study, we investigated the inflammatory and humoral responses to SARS-131

CoV-2 using maternal blood, cord blood, and placenta samples collected from pregnant women 132 who had either tested positive or negative for SARS-CoV-2 prior to admission and delivery at 133 the Johns Hopkins Hospital (JHH). We measured maternal and cord blood serum or plasma 134 anti-spike (S) and anti-S-receptor binding domain (RBD) IgG and neutralizing antibody (nAb) 135 responses to SARS-CoV-2, whole blood proinflammatory cytokine mRNA expression, as well as 136 placental cytokine and FcRn expression. Furthermore, we compared antibody responses to an 137 outpatient non-pregnant cohort of women with confirmed COVID-19. 138 139 Materials and Methods 140 S tud y P artic ip an ts , s ample c ollec tion , and s torag e 141 P regnancy C ohort. Pregnant women were recruited by convenience sampling through Johns 142

Hopkins Hospital outpatient obstetric clinics and the JHH Labor & Delivery unit prior, or after 143 delivery of the patient. We utilized discarded maternal blood, discarded neonatal cord blood, 144 and a small placental sample collected during admission for delivery. Patients were contacted, 145 informed of the study, and consented by phone to decrease face to face exposure due to 146 concern of SARS-CoV-2 spread/infection. Basic demographic information and clinical data, 147 including info on the history of SARS-CoV-2 testing (usually via the POCT nasopharyngeal 148 swab) was collected from the patient's medical record. Blood samples were collected into gold 149 top SST tubes and purple top EDTA tubes. The top SST tubes were inverted several times, 150 before being centrifuged for 10 minutes at 3000 rpm at 22°C. Then, both maternal and cord 151 whole blood and serum samples were aliquoted and stored at -80°C. Placental samples were 152 collected after delivery and were not treated with any preservatives or reagents. Samples were 153 J o u r n a l P r e -p r o o f processed using two different methods for both the maternal and fetal sides; placental tissue 154 was either frozen at -80°C immediately or was placed in RNAlater for 48 hours prior to -80°C 155 storage. To obtain tissue that was representative of the placental sample, half thickness 156 samples using a disc tissue punch were taken from two different locations on each side of the 157 placenta. Thus, ultimately, each method of processing placental tissue had two tissue punches 158 from different locations on a given side of the placenta. including that regarding the history of SARS-CoV-2 testing, was collected from the patient and 168 the patient's medical record. Participants in this study attended a research clinic visit on average 169 42.2 days after COVID-19 symptom onset (range 29-92 days), at which blood was drawn. 170

Approximately 25 ml of whole blood was collected in Acid Citrate Dextrose glass tubes. 171

Peripheral blood mononuclear cells were separated, and the remaining plasma was stored in 1 172 ml aliquots at -80 o C. Plasma was defrosted and then heat inactivated at 56 o C for 30 minutes 173 prior to serologic assays. The study was approved by the Johns Hopkins School of Medicine 174

Institutional Review Board. 175

Total RNA was extracted from placental tissue samples using the RNeasy Plus Mini Kit 178 (Qiagen) or from whole blood using NucleoSpin RNA Blood Kit (Macherey-Nagel). 179

Complementary (c) DNA synthesis in a 40-μL reaction was performed using Bio-Rad iScript™ 180 cDNA Synthesis Kit (Bio-Rad). TaqMan® (Thermo Fisher Scientific) mRNA assays were run for 181 analysis. The primers used were IL-1β (Table 1 ; Integrated DNA Technologies) and IL-6 ( Table  182 1; Integrated DNA Technologies). mRNA expression was calculated relative to housekeeping 183 genes: 18S (Hs99999901_s1; Applied Biosystems) and Actin ( The protocol was adapted from a published protocol from Dr. Florian Krammer's laboratory 17 , as 188 described in Klein et al., 2020 18 . Briefly, ninety-six-well plates (Immulon 4HBX, Thermo Fisher 189 Scientific) were coated with either full-length S protein or S-RBD at 4oC overnight. Coating 190 buffer was removed, and plates were washed and then blocked for 1 hour at room temperature. 191

All plasma samples were heat inactivated at 56oC on a heating block for 1 hour before use. 

The plasma neutralizing antibody (nAb) protocol was adapted from Dr. Andrew Pekosz's 210 laboratory 19 , as described in Klein et al., 2020 18 . Briefly, infectious virus (SARS-CoV-2/USA-211 WA1/2020) was added to two-fold diluted plasma at a final concentration of 1 × 104 TCID50/mL 212 (100 TCID50 per 100 μL). Samples were added to VeroE6-TMPRSS2 cells in sextuplet for 6 213 hours at 37˚C. The inocula were removed, fresh IM was added, and the plates were incubated 214 at 37˚C for 2 days. Cells were fixed by the addition of 150 μL of 4% formaldehyde per 215 well, incubated for at least 4 hours at room temperature, and then stained with Napthol Blue 216

Black (MilliporeSigma). The nAb titer was calculated as the highest serum dilution that 217 eliminated the cytopathic effect in 50% of the wells. 218 219

Western blotting was used to measure the protein expression of FcRn in placenta. To prepare 221 tissue lysate, tissue was homogenized on ice in RIPA lysis buffer (Sigma-Aldrich) with 222 proteinase inhibitor (Sigma-Aldrich) and phosphatase inhibitor cocktail 2 (Sigma-Aldrich). The 223 homogenized specimens were then placed on ice for 15 min and centrifuged at 14,000 rpm for 224 20 min at 4°C. The resulting supernatants were collected for further experiments. Total protein 225 was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE, Bio-226 Rad) using 4%-15% gels (Bio-Rad), and then, transferred onto nitrocellulose membranes (Bio-227 Rad) using semidry transfer device (Trans-Blot® Turbo™, Bio-Rad). Membranes were blocked 228 with 5% of bovine serum albumin (BSA, Sigma-Aldrich) in Tris-buffered saline (Corning) plus 229 0.1% of Tween-20 (Sigma-Aldrich) (TBST) for 15 min at room temperature and incubated with 230 primary antibodies in 5% of BSA at 4°C overnight, then, washed using TBST. FcRn antibody 231

(1:1000, Santa Cruz) and GAPDH (control marker, 1:1000, Abcam) were used for primary 232 antibodies. ECL (GE Healthcare) was used for detection using the ImageQuant LAS 500 (GE 233

Healthcare), and densitometric analysis was performed using ImageJ (National Institutes of 234

Health; http://rsb.info.nih.gov/ij/). isotypes and assays with days since the initial SARS-CoV-2 positive test or days since symptom 250 onset were assessed using the Spearman correlation coefficient. The data were then log 251 transformed for visualization. Finally, a generalized linear model was used to determine if the 252 association between days since the initial SARS-CoV-2 positive test or days since symptom 253 onset and antibody responses differed by pregnancy status (pregnant, non-pregnant) . All 254 analyses were two-tailed tests with a significance threshold of p < 0.05. 255

Cohorts. Two cohorts were included in this study: the pregnant cohort, consisting of 33 pregnant 257 women who either tested positive (n=22) or negative (n=11) for SARS-CoV-2 prior to delivery (in 258 inpatient or Labor and Delivery settings) at the JHH, and the non-pregnant cohort, consisting of 259 women within reproductive age (18-48 years of age), as defined by WHO 16 (n=17) who tested 260 positive for SARS-CoV-2 at an outpatient clinical testing site within the JHH Health System. 261

Comparing demographic characteristics between SARS-CoV-2 positive and negative pregnant 262 women revealed differences in maternal age at delivery, race, and ethnicity. SARS-CoV-2 263 positive pregnant women gave birth at a younger age (median=27; IQR 23-34) compared to 264 SARS-CoV-2 negative pregnant women (median=32; IQR 29-35) (p<0.05, J o u r n a l P r e -p r o o f outcomes 2,21,22 , we measured IL1β mRNA expression in maternal blood (total, n=27; positive, 282 n=18; negative, n=9), cord blood (total, n=29; positive, n=20; negative, n=9), and the maternal 283 (total, n=11; positive, n=8; negative, n=1) and fetal (total, n=26; positive, n=19; negative, n=7) 284 sides of placentas, which did not differ between SARS-CoV-2 positive and negative pregnant 285 women ( Figure 1A-D) . To assess whether the expression of IL1β differed depending on the 286 number of days between a pregnant woman's PCR test and blood sample collection, maternal 287 blood IL1β mRNA expression was compared based on the time window between diagnosis and 288 blood collection (total, n=27; positive, n=18; negative, n=9). Day 14 was chosen for analysis 289 based on the incubation period of SARS-CoV-2, which extends to 14 days after symptom 290 onset 23 . IL1β expression in maternal blood was higher in samples collected within 14 days of a 291 positive SARS-CoV-2 test compared with samples collected > 14 days after test, representative 292 of an acute, as opposed to chronic, inflammatory response (p<0.05; Figure 1E ). 293

We measured IL6 mRNA expression in maternal and fetal blood and tissue from our SARS- Figure 3A) . 309

In contrast, pregnant women had significantly lower anti-S-RBD IgG titers than non-pregnant 310 women (p<0.05, Figure 3B ). Titers of nAb, however, which correlate with anti-S-RBD 311 antibodies 27 , were measured and were not significantly different between pregnant and non-312 pregnant women (Figure 3C) . We observed, however, that significantly fewer pregnant women 313 To further explore how pregnancy altered the relationship between anti-S-RBD IgG and nAb, 317 titers were directly compared and revealed that anti-S-RBD IgG titers were higher than nAb 318 titers in both pregnant and non-pregnant women (p<0.001 Figure 4A Figure 4C,D) . Furthermore, time since symptom onset did not explain variation in anti-S-RBD 328

IgG or nAb responses among pregnant women with non-detectable as compared with 329 detectable nAb titers (Figure 4E,F) . Differences in the number of days between a PCR+ test or 330 symptom onset and sample collection also did not statistically explain variation in either anti-S-331 RBD IgG or nAb responses between pregnant and non-pregnant women (Figure 4C-F) . These 332 data suggest that, independent of time, pregnancy may reduce the quality of antiviral antibodies 333 against SARS-CoV-2; (pregnant, n=17; non-pregnant, n=17) . 334

Antibody transfer in SARS-CoV-2 infection. To assess whether antibody transfer from mother to 335 fetus was broadly affected by SARS-CoV-2 infection, SARS-CoV-2-specific antibody levels in 336 maternal (n=17) and cord blood (n=17) serum, FcRn expression, and anti-tetanus IgG titers 337

were assessed in SARS-CoV-2 positive (n=22) and negative women (n=11). Anti-S and anti-S-338 RBD IgG titers did not differ between maternal and cord blood serum samples (Figure 5A,B) ; 339 titers of nAb in maternal serum, however, were significantly greater than in cord blood serum (p 340 < 0.05; Figure 5C 

Our study provides preliminary evidence that pregnant women exhibit an inflammatory 352 response in maternal blood within 14 days of a PCR+ test, exhibit lower anti-S-RBD IgG titers, 353 and are less likely to have detectable nAb compared to non-pregnant women. Protein 354 concentrations of placental FcRn, a receptor essential for maternal transfer of antibodies to the 355 fetus were not affected by SARS-CoV-2 infection during pregnancy; reduced nAb responses 356 against SARS-CoV-2, however, were detected in cord blood. These results suggest that during 357 pregnancy there is an acute increase in IL-1β mRNA expression and reduced antiviral antibody 358 responses during SARS-CoV-2 infection. 359

The inflammatory response of pregnant women who experienced mild to moderate COVID-19 361 was characterized by greater IL-1β, but not IL-6, mRNA expression as has been reported in 362 severe male and non-pregnant female COVID-19 patients 25, 26 . Current studies highlight 363 differences in clinical manifestations between SARS-CoV-2 positive pregnant and non-pregnant 364 women, with some studies reporting differences in presenting symptoms, such as lower 365

incidence of fever and cough in pregnant women 28, 29 . There is growing evidence that SARS- trimester of SARS-CoV-2 positive women was also perturbed, which could impact the transfer of 407 SARS-CoV-2-specific antiboides 43 . In addition to tetanus-specific antibodies, influenza and 408 based on time of delivery, and sample collection from non-pregnant women was based on 435 symptom presentation. While there was a significant difference in age between the cohorts, all 436 women in this study were within reproductive ages 16 . Due to our inability to know precisely when 437 each participant was infected with SARS-CoV-2, we used the number of days between a SARS-438

CoV-2 PCR test and blood collection as the metric to assess cytokine responses, and 439 additionally used the number of days since symptom onset to evaluate humoral responses over 440 time. These metrics may not accurately represent the time since initial infection, as symptom 441 onset is self-reported and studies have reported PCR positivity for extended periods of time past 442 the initial infection 48,49 . Further, differences in blood volume between individuals, and throughout 443 gestation in pregnant women could lead to variability in antibody titers. 444

Our results demonstrate potential differences in the pathogenesis of SARS-CoV-2, 446 including inflammatory and antibody responses to the virus, between pregnant and non-447 pregnant women. It is well-established that immune responses change dramatically during 448 pregnancy in order to accommodate the developing fetus 50 . Therefore, understanding the 449 impact of SARS-CoV-2 infection during pregnancy on the maternal immune system, and how 450 these changes alter maternal and fetal susceptibility to disease is crucial for the development of 451 vaccines and other therapeutics for COVID-19. In addition to further investigations of short-and 452 long-term consequences of SARS-CoV-2 infection in pregnancy, the safety, immunogenicity, 453 and efficacy of SARS-CoV-2 vaccines in pregnant women must be considered. 

COVID-19 in pregnancy: Placental and neonatal 472 involvement

Characteristics and Maternal and Birth Outcomes of Hospitalized Pregnant Women with 475

Laboratory-Confirmed COVID-19-COVID-NET, 13 States

Update: Characteristics of Symptomatic Women 477 of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy 478

Pregnancy Outcomes and Maternal Deaths among Pregnant Patients with SARS-CoV-2 482

Infection in Washington State

SARS-CoV-2 Infection in Pregnancy -SET-NET, 16 Jurisdictions

Role of interferons and cytokines in pregnancy and fetal 489 development

Risks associated with viral infections during pregnancy The Journal of 491

Role of Inflammation in Virus 493

Maternal immune activation: Implications for neuropsychiatric 495 disorders. Science (80-)

Maternal immune activation: Implications for neuropsychiatric 497 disorders. Science (80-)

The Immune System in Pregnancy: A Unique Complexity

Vertically Transferred Immunity in Neonates: Mothers, Mechanisms 501 and Mediators

The clinical course of COVID-19 in the outpatient 505 setting: a prospective cohort study on behalf of the Ambulatory COVID Study Team** 5

Guidelines for Their Generation, Interpretation and Analysis for Global Monitoring

SARS-CoV-2 Seroconversion in Humans: 509 A Detailed Protocol for a Serological Assay

age, and hospitalization drive antibody

Coronavirus Disease

Laboratory characteristics of pregnant compared 559 to non-pregnant women infected with SARS-CoV-2

SARS-CoV-2 Vaccines: Status Report

Antibodies in Infants Born to Mothers with COVID-19

SARS-CoV-2 seroprevalence among 567 parturient women in Philadelphia

CoV-2 Viral Load , Transplacental Antibody Transfer , and Placental 571 Pathology in Pregnancies During the COVID-19 Pandemic

Compromised SARS-CoV-2-specific placental 574 antibody transfer. Cell

Longitudinal analysis of antibody response 576 following SARS-CoV-2 infection in pregnancy: from the first trimester to delivery

Dissecting antibody-mediated protection against SARS-CoV-2

Neutralizing Antibody Responses to SARS-CoV-2 in a 581

COVID-19 Recovered Patient Cohort and Their Implications

Compromised SARS-CoV-2-specific placental 584 antibody transfer

Standardization of ELISA protocols for 586 serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling

Maternal immune activation alters 589 fetal brain development through interleukin-6

Vaccination Considerations for People who are Pregnant or Breastfeeding | CDC

Humoral response and PCR positivity in patients 597 with COVID-19 in the New York City region, USA: an observational study

COVID-19 real-time RT-PCR: Does positivity on follow

The psychoneuroimmunology of pregnancy

A-D) Maternal blood, cord blood, and maternal and fetal side placental IL1β 638 expression between SARS-CoV-2 positive (P(+)) and negative (P(-)) samples in the pregnant 639

E) Maternal blood IL1β expression analyzed as a function of symptom expression and 640 days between SARS-CoV-2 PCR positive test and blood sample collection

at Day 14; significance denotes comparison of samples collected within 14 days of a positive 642

SARS-CoV-2 test with samples collected > 14 days after test. Maternal blood n= 27; cord 643 blood=29; maternal side placenta n=11

Dunn's multiple comparisons or Mann-Whitney test

Figure 2. IL6 expression in maternal and fetal samples. Maternal and fetal blood and 647 placentas were used to detect IL6 gene expression relative to the housekeeping genes (HKG)

A-D) Maternal blood, cord blood, and maternal and fetal side placental IL6 649 expression between SARS-CoV-2 positive (P(+)) and negative (P(-)) samples in the pregnant 650

E-H) Maternal blood, cord blood, and maternal and fetal side placental IL6 expression 651 in pregnant women who were asymptomatic (P-A), symptomatic (P-S)

(I) Maternal blood IL6 expression analyzed as a function of symptom expression 653 and days between SARS-CoV-2 PCR positive test and blood sample collection; dashed line 654 located at Day 14. Maternal blood n= 27; cord blood=29; maternal side placenta n=11

S-receptor binding domain (RBD), as well as whole virus 660 neutralizing antibodies (nAb). (A) Anti-S IgG, (B) anti-S-RBD IgG, and (C) nAb area under the 661 curve (AUC) titrations in serum or plasma from pregnant (P) (n=17) and non-pregnant (NP) 662 (n=17) women. The dashed line denotes the median AUC for

Above each box-plot is the proportion of samples with detectable antibody; *p<0

Dunn's multiple comparisons, Wilcoxon exact, or Chi-square tests

Association between anti-Spike-receptor binding domain (S-RBD) IgG and 667 neutralizing antibody (nAb) titers in pregnant and non-pregnant women. (A) Comparison 668 between anti-S-RBD IgG and nAb AUC in pregnant women

Comparison between anti-S-RBD IgG and nAb AUC in non-pregnant 671 women. (C,D) Anti-S-RBD IgG AUC and nAb analyzed as a function of detectability of nAb and 672 days between SARS-CoV-2 PCR positive test and blood sample. (E,F) Anti-S-RBD IgG AUC 673 and nAb analyzed as a function of detectability of nAb and days since symptom onset and blood 674 collection

Effects of SARS-CoV-2 infection on antibody transfer from mother to fetus

) nAb area under the curve (AUC) titrations in maternal 679 serum and cord blood serum in SARS-CoV-2 positive pregnant women. (D) Western blot 680 analysis for the neonatal Fc receptor (FcRn) protein in placentas from SARS

SARS-CoV-2 (-) women, n=35. (E) Quantification of FcRn western blot analysis relative to 682 GAPDH was analyzed in placentas from SARS-CoV-2 positive (P(+)) and negative

Maternal and (G) cord blood serum anti-tetanus IgG titers in SARS-CoV-2 684 positive and negative samples in the pregnant cohort; maternal serum n=35

pertussis-specific antibody transfer was not affected by SARS-CoV-2 infection 43 . Overall, these 409 results reiterate that non-SARS-CoV-2-specific antibody transfer is intact in SARS-CoV-2 410 positive women, but that SARS-CoV-2-specific antibody transfer mechanisms may be 411 compromised by infection. 412

These preliminary observations suggest that pregnant women who are infected with 414 SARS-CoV-2 may have an altered cytokine and humoral response compared to non-pregnant 415 women, which must be verified in a larger clinical cohort. Specifically, we report reduced anti-S-416 RBD IgG responses and a reduction of nAb production in a subset of pregnant women, 417suggesting that humoral immunity to SARS-CoV-2 infection during pregnancy is reduced as 418 compared to non-pregnant individuals. Increased cytokine activation at the maternal-fetal 419 interface can have adverse implications for the developing fetus 45 ; therefore, children born to 420 mothers infected with SARS-CoV-2 during pregnancy should be longitudinally observed to 421 assess long-term outcomes. With mRNA-based vaccines against SARS-CoV-2 now available, 422 the unique biological state of pregnancy needs be considered 46 . None of the SARS-CoV-2 423 vaccine candidates included pregnant women in their Phase III trials. The CDC acknowledges 424 the lack of data for vaccine efficacy in pregnant women and urges women to consult with their 425 healthcare provider prior to vaccination 47 . This is a real burden to place on pregnant women. We 426 urge greater use of animal models to assess the immunogenicity and reactogenicity of the 427 approved SARS-CoV-2 vaccine platforms to provide some indication of how pregnancy may or 428 may not alter responses, adverse reactions, and protection from infection and disease 46 . 429

Limitations of this study include the small sample size as well as significant differences 431 in age, race, and ethnicity between SARS-CoV-2-infected pregnant and non-pregnant women. 432These differences are attributable to our reliance on convenience sampling and are a result of 433 differences in participant recruitment, in which sample collection from pregnant women was 434